Objective: Our objective was to evaluate the efficacy and safety of sunitinib following at least one course of radioactive iodine treatment in patients with advanced differentiated thyroid cancer (DTC). The study endpoints included best response rate (including best objective response rate) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, measurement of serum thyroglobulin (Tg), and toxicity evaluation. Design and methods: This was a single center, nonrandomized, open-label, phase 2 clinical trial. In total, 23 patients were enrolled and were treated with a starting daily, oral dose of 37.5 mg sunitinib. Patients were evaluated with imaging, laboratory tests, and physical examination periodically per protocol. Results: The mean best response was a decrease of 17.2% (S.D. 22.8) in tumor sum from baseline. Six (26%) patients achieved a partial response (PR), and 13 (57%) had stable disease (SD) for a clinical benefit rate (PRCSD) of 83%. The overall median PFS was 241 days (interquartile limits, 114-518). No statistically significant difference was observed between the medians of the baseline and post-treatment Tg values (PZ0.24). The most common adverse events included grades 1 and 2 decreases in blood cell counts (especially leukocytes), diarrhea, fatigue, hand-foot skin reaction, nausea, musculoskeletal pain, and hypertension.
Introduction
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with 62 450 new cases expected to be diagnosed in 2015 in the USA (1). DTC is classified histologically as papillary, follicular (including Hürthle cell), or poorly differentiated (2). In general, patients with DTC have an excellent prognosis and 10-year survival rate ranging between 80 and 95% (3, 4). DTC patients with distant metastases represent a very heterogeneous group with 10-year survival rate ranging from 26 to 70% (5, 6) , but generally, the prognosis is worse with most authors reporting a 10-year survival rate of w40% (7) . Development of recurrent disease significantly worsens prognosis. DTC recurrence rate has been reported to be 1.4-23% (8, 9) and depends on the initial and ongoing risk stratification (10) . The mortality of patients with a recurrence has been shown to be as high as 38-69% (11, 12) . Furthermore, 2-5% of patients with initially differentiated tumors can develop refractoriness to radioiodine and iodine-131 ( 131 I)-negative metastases. Loss of differentiation is generally associated with a poor prognosis (13) . Patients with 131 I-positive metastases have demonstrated a 60%
10-year survival in comparison to 10% for patients with 131 I-negative metastases (14) . It is apparent that new therapeutic strategies are needed in order to improve the prognosis in patients with aggressive disease. Tyrosine kinase inhibitors (TKIs) have emerged as a promising therapeutic strategy, targeting a variety of tyrosine kinases based on the molecular biology of tumors. Thyroid tumors are highly vascular, and overexpression of the vascular endothelial growth factor receptor (VEGFR) has been reported in DTC (15) . Likewise, overexpression of the platelet-derived growth factor receptor (PDGFR) is well-established in thyroid cancer, and PDGFR-a has been associated with lymph node metastases in papillary thyroid cancer (PTC) (16) . The RET/PTC rearrangements are one of the most common genetic alteration described in PTC, and in the USA, the prevalence of the mutation has been reported to be 11-43% (17, 18) . As a result, a TKI that would target those kinases could potentially be effective in the treatment of DTC.
Sunitinib is a small molecule multi-TKI. It targets VEGFR, PDGFR, RET, the stem cell factor receptor KIT, and the FMS-like tyrosine kinase 3 ligand receptor (19) . Sunitinib is approved from the US Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma, gastrointestinal (GI) stromal tumor after disease progression on or intolerance to imatinib, and progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Kim et al. (20) studied the effect of sunitinib on thyroid oncogenic RET/PTC kinases, which are known to mediate thyroid cancer progression. By using an in vitro kinase assay, they discovered that sunitinib inhibited the phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner. Sunitinib was, therefore, considered to be a potentially highly effective TKI of the RET/PTC oncogenic kinase. These data, along with the effect of sunitinib on VEGFR and PDGFR, prompted us to initiate a single-center, phase 2 clinical trial in order to evaluate the efficacy and safety of sunitinib in patients with advanced DTC.
Patients and methods

Patients
Eligible patients were R18 years old with histologically confirmed DTC (e.g. PTC, follicular thyroid cancer, or poorly DTC) that had evidence of metastatic, residual, recurrent, or progressive disease (PD). All patients during enrollment demonstrated distant metastasis being classified as either stage 2 (younger than 45 years old) or stage 4C by American Joint Committee on Cancer. They all had been previously treated with at least one course of radioactive iodine (RAI) therapy for curative purposes, but their disease had progressed post-RAI, and curative measures were no longer effective. All patients had at least one measurable site of disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). RECIST 1.1 was published in 2009 and quickly became the standard of care for the evaluation of solid tumors. For that reason (and because our study was initiated in 2008), we repeated the response grids (of all patients that had been evaluated with RECIST 1.0) using RECIST 1.1. In order to be included in the study, patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status %2, life expectancy more than 3 months, serum aspartate transaminase (AST) and serum alanine transaminase (ALT) %2.5! upper limit of normal (ULN), or AST and ALT %5! ULN if liver function abnormalities are due to underlying malignancy, total serum bilirubin %1.5! ULN, serum albumin R3.0 g/dl, absolute neutrophil count R1500/ml, platelets R100 000/ml, hemoglobin R9.0 g/dl, and serum creatinine %1.5! ULN. Premenopausal women were required to have a negative pregnancy test, while all patients with childbearing potential agreed to use effective contraception.
Patients were excluded if they had received prior systemic chemotherapy or targeted therapy within 3 months prior to sunitinib initiation, prior external beam radiation therapy (EBRT) to the target lesions, and/or prior treatment with sunitinib. Patients were also excluded if they had history of any other carcinomas within the last 5 years (except for cured basal cell carcinoma of the skin and cured in situ cervical cancer), serious uncontrolled concomitant disease that could compromise study participation, active human immunodeficiency virus infection, lack of physical integrity of the upper GI tract or malabsorption syndrome, and/or the inability to take oral medication. All patients provided written informed consent before enrollment into the trial. The study protocol was approved by the Local Institutional Review Board. Tables 1, 2 and 3, see section on supplementary data given at the end of this article). Screening evaluation was performed at baseline with a physical examination, medical history, electrocardiogram (EKG), and laboratory evaluations including thyroid testing, urinalysis, and imaging modalities including neck ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET)-diagnostic CT, and echocardiography. During the first four cycles, patients were evaluated at the end of each cycle. After that time period, patients were evaluated once every 4-8 weeks/ protocol, alternating physical exam, medical history, and laboratory testing, with imaging modalities. All at each visit drug compliance and accountability, adverse events, concomitant medications, and therapies were assessed.
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Study endpoints
The primary endpoints of this study were best response rate (including best objective response rate) and progression-free survival (PFS). Secondary endpoints included overall survival (OS) and serum thyroglobulin (Tg) levels of patients that were on sunitinib. The study endpoints of best response, stable disease (SD), or PD were measured based on the findings on CT or MRI using RECIST 1.1. All responses and progressions were confirmed by a single, senior, study-designated radiologist blinded to clinical and laboratory data. Finally, another secondary endpoint was to assess the type, incidence, severity, timing, seriousness, and relatedness of adverse events. Adverse events were graded with the use of Common Terminology Criteria for Adverse Events (version 3).
Statistical analysis
The sample size was calculated according to Simon's phase 2 optimal two-stage study. For power calculation, we set the uninteresting level (P0)Z10%, desirable target level (P1)Z30% with aZ0.05, and powerZ90%.
Sunitinib would be ineffective or uninteresting if the true response (partial response (PR)Ccomplete response (CR)) probability was lower than 10%, and the regimen would be worthy of further study if the true response probability were R30%. The required sample size for stage 1 was 18 and 17 for an optional stage 2, for a total sample size of 35. If we observed more than two successes (objective responses, PR, and/or CR) among the first 18 patients, we would proceed to the second stage. Our final recruitment reached 23 patients. Estimates of PFS (time from starting study drug to progression or death, whichever occurred first) and OS (time from starting study drug to death from whatever reason) with associated interquartile limits were obtained using the Kaplan-Meier method. All enrolled patients who received at least 1 day of treatment were included in this intent-to-treat analysis.
Results
Baseline characteristics
Baseline patient characteristics are presented in Table 1 . In total, 74% (17) of the patients enrolled were male, while FDG-PET uptake (but no CT scan correlate), and bone metastases evidenced by sclerotic changes in the diagnostic CT scan in sternum and right superior pubic ramus. So, the treating team decided that this patient had PD that could not be detected at that time and decided that it would be to the patient's benefit to be enrolled to the current clinical trial. As per protocol, all patients had at least had one previous RAI treatment. The median number of RAI treatments was 3, and the mean cumulative dosage of RAI was 600.2 mCi. Previously, 13 (61%) had EBRT. No patient had been previously treated with a TKI.
Treatment administration
The first patient was enrolled in September 2008, and the study officially closed enrollment in October 2014. All data analysis was performed in February 2015. At the time of data analysis, all 23 patients were off the study. In total, 5/23 (22%) completed treatment, 9/23 (39%) came off the study due to PD, 1/23 (4%) came off the study due to a second primary carcinoma (ductal carcinoma in situ in breast), 3/23 (13%) came off the study due to side effects, 2/23 (8%) withdrew from the study, 1/23 (4%) came off the study in order to receive additional external radiation therapy to metastatic disease in the spine, 1/23 (4%) did not have the tumors evaluated due to severe toxicities leading to hospitalization, and 1/23 (4%) died of disease before the evaluation of the first month took place. The median duration of sunitinib treatment was nine cycles (range 1-24 cycles).
Efficacy
In total, 20 patients were assessable for response, but all 23 patients were included in this intent-to-treat analysis. The best response rate was calculated and is presented as a percentage to the sum of the longest diameters of lesions that were documented at enrollment. The response rates ranged from PD to a decrease in the sum of the target lesions by 69.92% by the RECIST 1.1. No patient achieved a CR (disappearance of all target lesions per RECIST 1.1) during the treatment with sunitinib. In total, 6/23 (26%) had a PR (decrease in sum of the longest diameter measurements R30%/RECIST 1.1). So, the objective response rate for our study was 26%. In total, 13/23 (57%) had SD (change in the sum of the longest diameter measurements between K30 and C20%/RECIST 1.1) as 
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Clinical Study A Bikas and others Sunitinib in advanced DTC 174:3their best response during treatment with sunitinib. In total, 1/23 (4%) had PD (increase in sum of the longest diameter measurements R20% or appearance of new lesion per RECIST 1.1). Therefore, the clinical benefit ratio of our study (PRCSD) was 83%. The best responses of all patients who had a clinical benefit from the study are depicted in the waterfall plot in Fig. 1 
Biochemical response
In total, 18 (78%) patients had evaluable serum Tg values at enrollment. Three (13%) were Tg antibodies positive, while 2 (9%) did not have a recent numerical value documented in their chart. During the first 2 months of treatment (with 17 patients available for evaluation), a decrease in the mean serum Tg values was noted. During the first 6 months of sunitinib (with 12 patients available for analysis), the decreasing trend persisted, but at the end of treatment (EOT) (with 18 patients evaluable), the serum Tg levels had increased compared to the 6 months levels, and no statistically significant difference was observed between the enrollment and the end-of-treatment Tg values (PZ0.24). In Table 2 , the percent change from baseline is presented for all evaluable patients at 2-6 months from the beginning of treatment and at the EOT. At 2 months, 42% of patients had a decrease at their serum Tg levels by more than 50%, while at 6 months, 50% of evaluable patients recorded the same level of decrease.
Adverse events
Sunitinib was generally well-tolerated. In total, 3/23 (13%) discontinued treatment as a result of side effects (nZ1 due to neutropenia and nZ2 due to hypertension). In total, 1/23 (4%) did not have the tumors evaluated due to severe toxicities leading to hospitalization (due to diarrhea, volume depletion, and hyponatremia). In all, 6/23 patients (26%) required a dose reduction from the initial 37.5-25 mg/once per day due to adverse events (nZ3 due to hand-foot syndrome; nZ1 due to diarrhea; nZ1 due to hypertension; and nZ1 due to GI distress, anorexia, and fatigue). All observed adverse events are listed in Table 3 . Treatment-related adverse events were predominantly grade 1 or 2. The most common were leukopenia (83%), thrombocytopenia (57%), fatigue (52%), diarrhea (52%), musculoskeletal pain (43%), and hand-foot syndrome (39%). Grade 3 adverse events were more infrequent, with the most commonly encountered being leukopenia (13%), hypertension (13%), hand-foot syndrome (9%), and anorexia (9%). All the rest grade 3 events did not exceed 4% (nZ1) of the patients. No grade 4 or 5 adverse events were documented in the study. In total, 7/23 (30%) patients needed a dose adjustment in thyroid hormone replacement therapy due to inappropriately elevated thyroid-stimulating hormone during sunitinib treatment.
Discussion
The unraveling of the molecular basis and the pathobiology of thyroid carcinomas has allowed the development of multi-target drug therapies that have revolutionized the way DTC is addressed. TKIs have gained promise in an effort to control DTC. The role of VEGFR, PDGFR, and RET tyrosine kinases is well-established in the pathogenesis of advanced stage DTC. We conducted a phase 2 clinical trial examining the response of patients with advanced, progressive DTC to sunitinib, an oral small molecule multi-kinase inhibitor. The median PFS in our 
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Clinical Study A Bikas and others Sunitinib in advanced DTC 174:3study was 241 days, while the median OS was 1694 days. The clinical benefit ratio (PRCSD) was 83%, and the mean best response change from baseline was K17.2% (S.D.Z 22.8%). Our clinical trial is, to the best of our knowledge, the first phase 2 clinical trial that has examined the effect of sunitinib solely on DTC, ensuring a homogeneous study population. Two phase 1 clinical trials reported a PR in two patients with thyroid cancer (one patient in each study) after treatment with sunitinib (21, 22) . Several groups have initiated phase 2 clinical trials of sunitinib in thyroid cancer. Carr et al. (23) included 35 patients in their study (33 evaluable), 28 of whom had DTC and seven had medullary thyroid cancer (MTC). Despite the obvious limitation of not reporting the results separately for DTC (26, 27) . More specifically, lenvatinib prolonged PFS by almost 15 months (18.3 months vs 3.6 months; hazard ratio (HR) 0.21; P!0.001). Sorafenib significantly increased the median PFS in the treatment group when compared to the control group (10.8 months vs 5.8 months; HR 0.59; P!0.0001). However, there is an imperative need to have available a variety of targeted therapies because of the diverse pathogenesis of advanced DTC. Our data demonstrate that sunitinib was effective against thyroid cancer, and this TKI could be further studied in that direction.
Despite the fact that TKIs have demonstrated a significant anti-neoplastic effect in studies performed in thyroid cancer, they do not represent a definitive form of therapy for the vast majority of patients. They are medications that can decelerate, or even halt, the progression of disease. However, the question that arises is what should be a feasible therapeutic option for patients that have failed a first-line TKI, such as sorafenib or lenvatinib. There is accumulating evidence that salvage therapy with a different TKI can be beneficial for patients that have already failed a first-line TKI (28) . Salvage therapy TKIs can be effective even if they have a similar mechanism of action with the first-line agent. In that context, agents such as sunitinib may be extremely useful in the treatment of patients that have aggressive and/or progressive DTC.
The dosing and schedule used in our study was generally well-tolerated by the patients. The 37.5 mg/once daily dose that we used was consistent with what some previous investigators have used (23) , but different from the maximum dose of 50 mg in a schedule 4/2 schedule (4 weeks on therapy and 2-week rest) used in other studies (24, 25) . We decided to use a continuous regimen of sunitinib to minimize the possibility for tumor escape during treatment and the lower dose of 37.5 mg daily in order to compensate for the deletion of the rest period. The most common adverse events were either grade 1 or 2, with hematologic toxicity (especially leukopenia), fatigue, and diarrhea being the most prevalent. However, the fact that sunitinib is a systemic therapy with a variety of offtarget effects is illustrated by the percentages of patients in whom discontinuation of treatment (13%) or dose reduction (26%) was required.
In summary, sunitinib in our study was well-tolerated and demonstrated significant anti-tumor activity in patients that had PD, despite having undergone at least one (and usually multiple) treatments with RAI. More studies in larger-scale cohorts are needed in order to clarify whether sunitinib can be used as a first-line TKI in those patients or should be used as a salvage therapy after patients' progression with one of the first-line agents.
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